Want to see GMAB full AI Analyst Report?
GMAB Stock Chart & Stats
$34.36
$0.08(0.28%)
At close: 4:00 PM EDT
$34.36
$0.08(0.28%)
Day’s Range― - ―
52-Week Range$23.62 - $40.17
Previous CloseN/A
Volume1.08M
Average Volume (3M)3.37M
Market Cap
$22.80B
Enterprise Value$20.72B
Total Cash (Recent Filing)$1.50B
Total Debt (Recent Filing)$5.27B
Price to Earnings (P/E)29.8
Beta0.78
Next Earnings
Nov 05, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.28
Shares Outstanding624,058,530
10 Day Avg. Volume4,620,532
30 Day Avg. Volume3,372,065
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)3.28
Price to Sales (P/S)5.14
P/FCF Ratio16.65
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue5.02
Enterprise Value/Gross Profit5.39
Enterprise Value/Ebitda16.99
Forecast
1Y Price Target
$99.70Price Target Upside190.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)1.18
Revenue Forecast (FY)$4.48B
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthStrong H1 growth and a raised full-year outlook indicate broadening commercial traction across royalties and product sales. Sustained expansion from DARZALEX, EPKINLY, and the wider portfolio can support reinvestment in launches and development while strengthening Genmab’s earnings base.
EPKINLY Commercial MomentumRapid EPKINLY growth, community-practice adoption, and expansion across approved indications provide a durable product-specific growth engine. Increasing utilization can deepen Genmab’s commercial footprint and support recurring product revenue as additional lymphoma opportunities develop.
Clinical And Regulatory ExpansionThe positive frontline DLBCL Phase 3 result materially expands the potential role of epcoritamab beyond existing indications. If regulatory engagement is successful, the combination could broaden Genmab’s addressable market and reinforce its strategic position in hematologic oncology.
Bears Say
Sharp Margin CompressionMaterially lower operating and net margins show that recent growth is requiring a heavier cost burden or generating less profit per dollar of revenue. If pressure persists, reduced profitability could constrain internal funding for launches, pipeline investment, and commercial expansion.
Higher Leverage Reduces FlexibilityDebt now stands close to equity, representing a meaningful structural change in Genmab’s financial profile. Higher leverage can reduce flexibility to absorb weaker results or fund strategic opportunities, while adding financial obligations if profitability remains under pressure.
Competitive And Regulatory Execution RiskIntensifying competition across key indications may limit adoption, pricing power, or differentiation for Genmab’s pipeline assets. Regulatory uncertainty over confirmatory trials can also delay approvals and extend development timelines, making the long-term value of late-stage programs less predictable.
Genmab News
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $23.62 and its highest was $40.17 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is $22.80B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Nov 05, 2026 which is in 16 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Aug 06, 2026. The company reported $0.491 earnings per share for the quarter, beating the consensus estimate of $0.356 by $0.135.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 0.35.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 624,058,530 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.491 in its last earnings report, beating expectations of $0.356. Following the earnings report the stock price went up 1.948%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GMAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genmab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$99.70 (190.15% Upside)
$99.70 (190.15% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 4.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 24.8%
Last 30 Days ▲ 24.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.06%
12-Months-Change
Fundamentals
Return on Equity
13.58%
Trailing 12-Months
Asset Growth
93.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Genmab A/S
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
GMAB Company Deck
GMAB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Genmab presented a strongly positive commercial and financial performance in H1 2026 — double-digit revenue and operating profit growth, upgraded full-year guidance, robust Epkinly momentum, meaningful product sales (DARZALEX, EPKINLY, TIVDAK), and multiple late-stage clinical advances including a positive Phase III PFS readout and new Phase III initiations. The company also acknowledged execution uncertainties: several data readouts remain event-driven or immature (OS not yet mature), competition across key indications is intensifying, some trial timing/readout clarifications raised investor questions, and integration/IP/tax factors introduce near-term modeling uncertainty. On balance the operational and financial momentum and near-term catalyst calendar outweigh the challenges, supporting a constructive outlook.View all GMAB earnings summariesGMAB Stock 12 Month Forecast
Average Price Target
$99.70
▲(190.15% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.76% Mutual Funds
0.15% Other Institutional Investors
97.81% Public Companies and
Individual Investors